To address these limitations, we used the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database and a retrospective cohort from China to validate and gain insights into the clinical significance of incorporating CEA status in the staging and treatment of patients with CRC. This evidence concerns the gene CEACAM5 and colorectal carcinoma.